Central Garden & Pet Stock (NASDAQ: CENTA)

Central Garden & Pet (NASDAQ:CENTA) Stock, Quote.Headers.trade-ideas

Central Garden & Pet

Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGBA

ATNM

ATTO

BCLI

BDSX

BNSO

BROG

BURL

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CENTA

CFMS

CHRA

CING

CNEY

COMS

Core Scientific, Inc. - Class A Common Stock

CORZ

COSM

CYCN

DBGI

DLTR

DPRO

EQOS

Euda Health Holdings Limited - Ordinary Shares

EUDA

FDMT

FENG

FOXO

GHRS

GMDA

GOEV

GRAY

GRND

JACK

MANU

MLAB

MRTX

MSGM

NKLA

NOAH

NOTE

OBSV

PALI

PERF

POND

PRVB

PSNY

QTNT

ROAD

SANG

SatixFy Communications Ltd. Ordinary Share

SATX

SCPS

STBX

TFFP

TOPS

URBN

WAVD

WISA

Gainers


	Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on Iberian Airlines&#39; in-flight magazine, Ronda.


Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday

ARDX

BGNE

DADA

HLTH

NVAX

SLGC

SOUN

TDCX

U.S. stocks closed higher on Tuesday, with the Dow Jones gaining around 400 points. Here is the list of some big stocks recording losses in the previous session.

Dollar Tree, Dycom Industries, Chico&#39;s FAS And Other Big Losers From Tuesday

Intraday Update

AENZ

ELEV

FWBI

HILS

MGNX

SYTA

Gainers


	Palisade Bio, Inc.  (NASDAQ: PALI) shares jumped 99.1% to $4.42 after the company announced the FDA granted Fast Track designation to LB1148 for the acceleration of time to return of bowel function following surgery.


Why Dollar Tree Shares Are Trading Lower By 10%? Here Are 53 Stocks Moving In Tuesday&#39;s Mid-Day Session

Central Garden & Pet Company - Class A Common Stock Nonvoting

Central Garden & Pet Co

Centamin PLC

Centaur Media PLC

CENTAURUS ENERGY INC by Centaurus Energy Inc.

Centaurus Energy Inc

CENTAURUS METALS LTD ORD by Centaurus Metals Ltd.

Centaurus Metals Ltd

JP Morgan analyst Andrea Faria Teixeira maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) with a Neutral and lowers the price target from $40 to $38.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Central Garden & Pet, Lowers Price Target to $38

Truist Securities analyst Bill Chappell maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) with a Buy and raises the price target from $45 to $50.

Truist Securities Maintains Buy on Central Garden & Pet, Raises Price Target to $50

Fiscal 2024 Guidance
Central continues to expect fiscal 2024 non-GAAP EPS to be $2.00 or better ($2.50 or better before the February 2024 stock dividend).
This outlook reflects uncertain consumer demand and retailer dynamics and an environment of macroeconomic and geopolitical volatility. It includes modest carryover pricing actions to help mitigate inflationary headwinds. This outlook excludes the impact of any acquisitions, divestitures or restructuring activities that may occur during fiscal 2024, including any projects under the Cost and Simplicity program and the recent TDBBS acquisition. Central expects fiscal 2024 capital spending to be approximately $70 million.

Guidance

CENT

Central Garden & Pet Continues To Expect FY24 Non-GAAP EPS To Be $2.00 Or Better ($2.50 Or Better Before The February 2024 Stock Dividend) Vs $2.23 Est

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) reported quarterly earnings of $0.99 per share which beat the analyst consensus estimate of $0.80 by 23.75 percent. The company reported quarterly sales of $900.000 million which beat the analyst consensus estimate of $887.420 million by 1.42 percent. This is a 0.99 percent decrease over sales of $909.004 million the same period last year.

Earnings

Earnings Beats

Central Garden & Pet Q2 2024 Adj EPS $0.99 Beats $0.80 Estimate, Sales $900.000M Beat $887.420M Estimate

Truist Securities analyst Bill Chappell maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) with a Buy and raises the price target from $50 to $60.

Truist Securities Maintains Buy on Central Garden & Pet, Raises Price Target to $60-Report released on 8th February 2024

JP Morgan analyst Andrea Faria Teixeira maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) with a Neutral and raises the price target from $40 to $43.

JP Morgan Maintains Neutral on Central Garden & Pet, Raises Price Target to $43

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.17) by 105.88 percent. The company reported quarterly sales of $634.53 million which beat the analyst consensus estimate of $619.95 million by 2.35 percent. This is a 1.09 percent increase over sales of $627.66 million the same period last year.

Central Garden & Pet Q1 2024 GAAP EPS $0.01 Beats $(0.17) Estimate, Sales $634.53M Beat $619.95M Estimate

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) reported its Q1 earnings results on Wednesday, February 7, 2024 at 04:03 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 105.88%, reporting an EPS of $0.01 versus an estimate of $-0.17.
Revenue was up $6.87 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.18 which was followed by a 0.84% drop in the share price the next day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2023</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.07</td>
<td>0.07</td>
<td>1.35</td>
<td>1.45</td>
<td>0.94</td>
<td>0.94</td>
<td>-0.17</td>
<td>-0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.10</td>
<td>0.10</td>
<td>1.75</td>
<td>1.75</td>
<td>0.90</td>
<td>0.90</td>
<td>-0.16</td>
<td>-0.16</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>735.32M</td>
<td>735.32M</td>
<td>932.78M</td>
<td>1.03B</td>
<td>899.17M</td>
<td>899.17M</td>
<td>620.30M</td>
<td>620.30M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>750.15M</td>
<td>750.15M</td>
<td>1.02B</td>
<td>1.02B</td>
<td>909.00M</td>
<td>909.00M</td>
<td>627.66M</td>
<td>627.66M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Central Garden & Pet Q1 Earnings

ACLS

ADNT

ALCO

APPS

ARCC

ASGN

ASND

AVXL

AZTA

BABA

BARK

BERY

BLBD

CDAY

CFLT

CMRE

COTY

CRTO

CSGS

EEFT

ENTA

EQNR

FLNC

FLNG

FORM

FOXA

GEOS

GPRE

GPRO

HAIN

INTR

MCFT

MKSI

MPWR

MSGE

MTRX

NBIX

NOTV

NTGR

NVST

NWSA

OESX

ORLY

OSCR

PAHC

Earnings Scheduled For February 7, 2024

WIIM

Central Garden & Pet shares are trading lower after the company reported Q4 financial results and issued FY24 adjusted EPS guidance below estimates.

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) reported its Q4 earnings results on Monday, November 20, 2023 at 04:01 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 42.86%, reporting an EPS of $0.1 versus an estimate of $0.07.
Revenue was up $42.70 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.03 which was followed by a 0.3% drop in the share price the next day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.35</td>
<td>1.45</td>
<td>0.94</td>
<td>0.94</td>
<td>-0.17</td>
<td>-0.17</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.75</td>
<td>1.75</td>
<td>0.90</td>
<td>0.90</td>
<td>-0.16</td>
<td>-0.16</td>
<td>-0.04</td>
<td>-0.04</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>932.78M</td>
<td>1.03B</td>
<td>899.17M</td>
<td>899.17M</td>
<td>620.30M</td>
<td>620.30M</td>
<td>719.67M</td>
<td>719.67M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.02B</td>
<td>1.02B</td>
<td>909.00M</td>
<td>909.00M</td>
<td>627.66M</td>
<td>627.66M</td>
<td>707.44M</td>
<td>707.44M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Central Garden & Pet Q4 Earnings

<h3>Companies Reporting Before The Bell</h3>
&bull; Greenland Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTEC#NASDAQ">GTEC</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $24.26 million.
&bull; Pyxis Tankers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXS#NASDAQ">PXS</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $8.25 million.
&bull; BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is estimated to report earnings for its third quarter.
&bull; ReNew Energy Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNW#NASDAQ">RNW</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $109.71 million.
&bull; So-Young Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SY#NASDAQ">SY</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $55.38 million.
&bull; Enlight Renewable Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLT#NASDAQ">ENLT</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $65.70 million.
&bull; Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) is projected to report earnings for its third quarter.
&bull; Zepp Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $179.52 million.
&bull; Full Truck Alliance Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YMM#NYSE">YMM</a>) is projected to report earnings for its third quarter.
&bull; VEON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) is expected to report earnings for its third quarter.
&bull; Fanhua (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANH#NASDAQ">FANH</a>) is expected to report earnings for its third quarter.
&bull; Niu Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) is expected to report earnings for its third quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Techprecision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPCS#NASDAQ">TPCS</a>) is expected to report earnings for its second quarter.
&bull; Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) is likely to report quarterly loss at $0.16 per share on revenue of $3.40 million.
&bull; Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $735.32 million.
&bull; Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $735.32 million.
&bull; Remark Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARK#NASDAQ">MARK</a>) is estimated to report earnings for its third quarter.
&bull; Presto Automation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) is projected to report earnings for its third quarter.
&bull; Polished.com (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/POL#AMEX">POL</a>) is likely to report earnings for its third quarter.
&bull; Upexi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) is expected to report quarterly loss at $0.04 per share on revenue of $26.52 million.
&bull; Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) is expected to report quarterly loss at $2.00 per share on revenue of $20.60 million.
&bull; Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) is estimated to report earnings for its third quarter.
&bull; Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $305.16 million.
&bull; FinVolution Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>) is likely to report earnings for its third quarter.
&bull; Trip.com Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) is estimated to report earnings for its third quarter.
&bull; Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) is estimated to report quarterly earnings at $1.87 per share on revenue of $1.30 billion.
&bull; Fidelis Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIHL#NYSE">FIHL</a>) is projected to report earnings for its third quarter.
&bull; Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is projected to report quarterly earnings at $1.08 per share on revenue of $1.12 billion.
&bull; BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $460.52 million.
&bull; FS Credit Opp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSCO#NYSE">FSCO</a>) is expected to report earnings for its third quarter.
&bull; Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) is projected to report quarterly earnings at $1.35 per share on revenue of $1.68 billion.
&bull; Golub Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBDC#NASDAQ">GBDC</a>) is estimated to report quarterly earnings at $0.47 per share on revenue of $157.82 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

BLRX

BRBR

ENLT

FANH

FIHL

FINV

FSCO

GBDC

GTEC

KEYS

LEGN

MARK

PRST

TCOM

TPCS

UPXI

VEON

XELB

YALA

ZEPP

Earnings Scheduled For November 20, 2023

Acquisition Builds Scale and Adds eCommerce and Digital Capabilities to Core Pet Category
Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) ("Central"), a market leader in the Pet and Garden industries, announced today that it has acquired TDBBS, LLC ("TDBBS") from Bregal Partners. Based in Richmond, VA, TDBBS is a provider of premium natural dog chews and treats. The addition of TDBBS will expand Central's portfolio with bully and collagen sticks, bones and jerky, and further strengthen Central's eCommerce and digital capabilities.
"We are excited to welcome the TDBBS team into the Central Garden &amp; Pet organization," said Beth Springer, Interim CEO of Central. "Our Central to Home strategy is focused on building further scale in our two industries and growing leading brands consumers love. Adding TDBBS's established brands and digital capabilities solidifies our position in the large and growing dog treats and chews category and will strengthen our footprint with key customers."
Since 2008, TDBBS has developed and sold minimally processed dog treats and chews. Each of their three well-known brands (Best Bully Sticks&#xAE;, Barkworthies&#xAE; and Paw Love&#xAE;) offers a wide variety of natural, grain and gluten-free products that are low in fat and high in protein and made from limited ingredients. Their wholesome treats and chews keep dogs occupied while promoting overall health.
A pioneer in eCommerce, TDBBS was founded as a digitally native brand with a first-mover advantage. Today, the company's brands and websites are synonymous with the bully stick category. TDBBS sells its products online direct-to-consumer and through third-party platforms, as well as through pet specialty and select grocery, mass and club retailers.
"For over 15 years, TDBBS has been proud to offer the widest selection of high-quality natural dog treats and chews. We believe pets are family, and they deserve quality ingredients just like us. We are excited for this next chapter in our business as part of Central Garden &amp; Pet," said Tom Goundrey, CEO of TDBBS. "Central's resources, capabilities and expertise in the pet industry will be key to growing our business further."
Central was represented by Orrick as legal advisor. TDBBS was represented by Lazard as exclusive financial advisor and Dechert as legal advisor.
The transaction closed on November 3, 2023. Central will provide additional details on the acquisition during its fourth quarter and fiscal year-end earnings call later in November.

Central Garden & Pet Acquires Pet Treat Company TDBBS; No Financial Terms Disclosed

Keybanc analyst Bradley Thomas maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) with a Overweight and raises the price target from $46 to $50.

Keybanc Maintains Overweight on Central Garden & Pet, Raises Price Target to $50

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) reported its Q2 earnings results on Wednesday, May 3, 2023 at 04:02 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet missed estimated earnings by 4.26%, reporting an EPS of $0.9 versus an estimate of $0.94.
Revenue was down $45.37 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.01 which was followed by a 0.76% increase in the share price the next day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
<th>Q2 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.17</td>
<td>0.01</td>
<td>1.27</td>
<td>1.20</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.16</td>
<td>-0.04</td>
<td>1.39</td>
<td>1.27</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>620.30M</td>
<td>719.67M</td>
<td>997.93M</td>
<td>935.00M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>627.66M</td>
<td>707.44M</td>
<td>1.01B</td>
<td>954.37M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Central Garden & Pet Q2 Earnings

JP Morgan analyst Andrea Faria Teixeira maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) with a Neutral and lowers the price target from $41 to $38.

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Central Garden & Pet

Central Garden & Pet (CENTA) Forecast

Central Garden & Pet (NASDAQ:CENTA) Stock, Quote.Headers.trade-ideas